Sufferers received trebananib a median of 9
Sufferers received trebananib a median of 9.5 and 11.0 weeks in cohorts 2 and 4, respectively; motesanib was implemented a median of 67 and 87 times in those matching cohorts. 3, respectively (bothn= 1). Across both bevacizumab plus trebananib cohorts, the most frequent AEs included exhaustion (n= 8), diarrhoea (n =4), constipation (n= 3), nausea…